Clinical trials
Unresectable Hepatocellular Carcinoma clinical trials
Below are recruiting unresectable hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 154 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07317414RecruitingPhase 2
Beta-alanine for advanced liver cancer
This trial tests whether beta-alanine, a natural supplement, can help people with advanced liver cancer that cannot be removed by surgery. It aims to see if the treatment can slow tumor growth and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07305428Recruiting
Making large liver tumors removable with immunotherapy and focused radiation
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
Hong KongAges 18–80 - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT07227012RecruitingPhase 1/Phase 2
Study of a new drug for advanced liver cancer
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Irvine, CaliforniaAges 18 years+ - NCT07219459RecruitingPhase 2
New drug combo for liver cancer after PD-1/PD-L1 treatment fails
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Irvine, CaliforniaAges 18–100 - NCT06909708Recruiting
Comparing two liver cancer treatments for unresectable tumors
This trial compares two treatments for liver cancer that cannot be removed by surgery: SIRT (a type of internal radiation) and cTACE (a type of targeted chemo). It aims to see which is more effective for patients with limited tumor spread and good liver function.
Nanjing, JiangsuAges 18 years+ - NCT07209813RecruitingPhase 2
Immunotherapy plus TACE for liver cancer
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT07179900RecruitingPhase 2
Radiation plus two drugs for liver cancer that can't be removed
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Shijiazhuang, HebeiAges 18 years+ - NCT07175441RecruitingPhase 2
Testing a new drug combo for advanced liver cancer
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Baltimore, MarylandAges 18 years+ - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT05409482Recruiting
Areal-world test of camrelizumab plus apatinib for liver cancer
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
Fuzhou, FujianAges 18–75 - NCT06911255RecruitingPhase 1/Phase 2
Testing two immunotherapy drugs with chemoembolization for liver cancer
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
SeoulAges 19 years+ - NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Phoenix, ArizonaAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06880523RecruitingPhase 2
Adding lenvatinib to immunotherapy for liver cancer
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Calgary, AlbertaAges 18 years+ - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06737913RecruitingPhase 2
Study of adebrelimab and bevacizumab with liver chemo for advanced liver cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Lanzhou, GansuAges 18 years+ - NCT06551272RecruitingPhase 2
Gut bacteria change to help immunotherapy for liver cancer
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
BobignyAges 18 years+ - NCT06698250RecruitingPhase 2
Study of triple therapy for untreated liver cancer
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
Pittsburgh, PennsylvaniaAges 18 years+
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable hepatocellular carcinoma?
- Yes. Clin2 currently lists 154 recruiting unresectable hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.